Introduction

Next-generation sequencing (NGS) has revolutionized the field of molecular medicine by enabling rapid, high-throughput and cost-effective analysis of entire genomes, exomes and transcriptomes. Unlike traditional sequencing methods, NGS allows for comprehensive detection of genetic variations, including single nucleotide polymorphisms, insertions, deletions, copy number variations and structural rearrangements. This transformative technology has advanced our understanding of disease mechanisms, facilitated early diagnosis and enabled the development of personalized therapeutic strategies. In oncology, infectious disease management, rare genetic disorder diagnosis and pharmacogenomics, NGS has become an indispensable tool for both research and clinical applications. By providing detailed insights into the molecular landscape of health and disease, NGS continues to shape the future of precision medicine and improve patient outcomes.

Description

Next-generation sequencing (NGS) represents a significant advancement over traditional Sanger sequencing by offering massively parallel processing of millions of DNA fragments simultaneously. This scalability has drastically reduced both the time and cost required to sequence entire genomes, making genomic studies accessible to clinical and research laboratories worldwide. NGS platforms can generate comprehensive datasets that capture the full spectrum of genetic variation, from point mutations to large chromosomal rearrangements. Whole-genome sequencing (WGS) provides an unbiased view of the entire genetic landscape, while whole-exome sequencing (WES) focuses on protein-coding regions where most disease-causing mutations occur. Additionally, RNA sequencing enables transcriptome profiling, revealing insights into gene expression, splicing variants and non-coding RNA regulation. These approaches have accelerated discoveries in basic science while also laying the groundwork for translation into clinical medicine. Importantly, NGS technologies continue to evolve, with newer platforms offering increased read lengths, improved accuracy and faster turnaround times. Collectively, these innovations are redefining how genetic information is harnessed to study and treat human disease [2].

In oncology, NGS has had a transformative impact by uncovering the molecular basis of cancer and informing precision therapies. Tumor genome sequencing identifies driver mutations, gene fusions and copy number changes that contribute to oncogenesis. This molecular characterization allows clinicians to match patients with targeted therapies, such as tyrosine kinase inhibitors for EGFR-mutant lung cancer or BRAF inhibitors for melanoma. NGS-based liquid biopsies, which analyze circulating tumor DNA in blood samples, offer a minimally invasive approach for monitoring disease progression and therapeutic response. Furthermore, NGS enables detection of emerging resistance mutations, guiding adjustments to treatment regimens. Large-scale cancer genomics initiatives, such as The Cancer Genome Atlas (TCGA), have relied heavily on NGS to map the mutational landscapes of various tumor types. These insights have facilitated the development of molecular classifiers that stratify patients into prognostic groups and inform clinical decision-making. As a result, NGS has become an essential tool in the era of personalized oncology, improving both treatment outcomes and quality of life for patients [3].

Beyond oncology, NGS has played a crucial role in the diagnosis and management of rare genetic disorders. Many inherited diseases are caused by single-gene mutations or structural variants that were previously undetectable with conventional methods. Whole-exome and whole-genome sequencing allow clinicians to identify pathogenic variants in undiagnosed patients, often ending years of diagnostic uncertainty. For example, NGS has been instrumental in diagnosing neuromuscular disorders, metabolic syndromes and immunodeficiencies. In some cases, these molecular diagnoses directly inform targeted therapies or allow for enrollment in clinical trials of novel treatments. Furthermore, NGS supports carrier screening, prenatal testing and newborn screening, expanding opportunities for early intervention. Integration of sequencing data with bioinformatics and variant interpretation guidelines ensures that clinically relevant findings are accurately distinguished from benign polymorphisms. These advancements highlight the power of NGS in bringing precision medicine to patients with rare and complex diseases [4].

NGS has also advanced infectious disease research and clinical practice by enabling rapid identification and characterization of pathogens. Metagenomic sequencing allows unbiased detection of bacteria, viruses, fungi and parasites directly from clinical samples, bypassing the need for culture-based methods. This has been especially valuable in outbreak investigations, such as identifying novel viruses like SARS-CoV-2 and tracking their genomic evolution. NGS also facilitates antimicrobial resistance profiling by revealing genetic determinants of resistance, enabling clinicians to select appropriate therapies. In addition, NGS-based surveillance informs vaccine design and public health strategies by monitoring pathogen diversity and transmission dynamics. Pharmacogenomics is another area where NGS plays a pivotal role, as sequencing patient genomes reveals variations in drug-metabolizing enzymes that influence treatment efficacy and safety. Together, these applications underscore the versatility of NGS in advancing multiple domains of molecular medicine. As the technology continues to evolve, integration of NGS with artificial intelligence and big data analytics is expected to further enhance its diagnostic and therapeutic impact [5].

Conclusion

Next-generation sequencing has fundamentally transformed molecular medicine by bridging the gap between genetic discoveries and clinical application. Its ability to deliver comprehensive genomic insights has advanced diagnostics, enabled personalized treatment strategies and deepened understanding of disease biology across diverse fields, from oncology to infectious diseases. By uncovering the genetic underpinnings of rare disorders, identifying therapeutic targets in cancer and guiding public health responses to emerging pathogens, NGS has demonstrated its indispensable role in modern medicine. However, challenges remain, including data interpretation, ethical concerns, cost and the need for robust bioinformatics infrastructure. Despite these hurdles, the ongoing refinement of sequencing platforms and analytic tools continues to enhance accuracy, accessibility and clinical utility.<./p>

Acknowledgment

None.

Conflict of Interest

None.

Reference

1. Han J, Kraft P, Nan H, Guo Q, Chen C, et al. (2008). A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. Plos Genet 4: e1000074.

                     Google Scholar Cross Ref Indexed at

2. Bocklandt S, Lin W, Sehl ME, Sánchez FJ, Sinsheimer JS, et al. (2011). Epigenetic predictor of age. Plos One 6: e14821.

                     Google Scholar Cross Ref Indexed at

3. Courts C, Madea B (2010). Micro-RNA–a potential for forensic science?. Forensic Sci Int 203: 106-111.

                     Google Scholar Cross Ref Indexed at

4. Bhoyar RC, Jain A, Sehgal P, Divakar MK, Sharma D, et al. (2021). High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencing. Plos One 16: e0247115.

                     Google Scholar Cross Ref Indexed at

5. Lorenzi D, Fernández C, Bilinski M, Fabbro M, Galain M, et al. (2020). First custom next-generation sequencing infertility panel in Latin America: design and first results. JBRA Assist. Reprod, 24: 104.

                     Google Scholar Cross Ref Indexed at